EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Leishmania Vaccines: Current Development and Future Prospects

Andreina Ayala, Alejandro Llanes iD, Ricardo Lleonart iD, Carlos M Restrepo iD

Pathogens · 20.09.2024 · 13 (9) · 812

DOI: 10.3390/pathogens13090812 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 20.09.2024. Verfasst von Andreina Ayala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT-AIP), Pana…. Hauptthemen laut MEDLINE: Leishmania, Leishmaniasis, Leishmaniasis Vaccines, Vaccines, DNA. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría Nacional de Ciencia, Tecnología e Innovación, Sistema Nacional de Investigación (SNI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania. As approved human vaccines are not available, treatment and prevention rely heavily on toxic chemotherapeutic agents, which face increasing resistance problems. The development of effective vaccines against human leishmaniasis is of utmost importance for the control of the disease. Strategies that have been considered for this purpose range from whole-killed and attenuated parasites to recombinant proteins and DNA vaccines. The ideal vaccine must be safe and effective, ensuring lasting immunity through a robust IL-12-driven Th1 adaptive immune response. Despite some success and years of effort, human vaccine trials have encountered difficulties in conferring durable protection against Leishmania, a problem that may be attributed to the parasite’s antigenic diversity and the intricate nature of the host’s immune response. The aim of this review is to provide a thorough overview of recent advances in Leishmania vaccine development, ranging from initial trials to recent achievements, such as the ChAd63-KH DNA vaccine, which underscores the potential for effective control of leishmaniasis through continued research in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeishmaniaLeishmaniasisLeishmaniasis VaccinesVaccines, DNAAnimalsHumansVaccine Development

Stichwörter der Autor:innen

Leishmaniaimmunityleishmaniasistreatmentvaccinevaccine development

Substanzen

Leishmaniasis VaccinesVaccines, DNA

Autor:innen und Institutionen

  • Centro de Biología Celular y Molecular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT-AIP), Panama City 0843-01103, Panama.
  • Sistema Nacional de Investigación (SNI), Panama City 0801, Panama.

ORCID-Profile: Alejandro Llanes, Ricardo Lleonart, Carlos M Restrepo

Förderung

  • Secretaría Nacional de Ciencia, Tecnología e Innovación
  • Sistema Nacional de Investigación (SNI)

Zitieren

APA

Ayala, A., Llanes, A., Lleonart, R., & Restrepo, C. M. (2024). Advances in Leishmania Vaccines: Current Development and Future Prospects. Pathogens, 13(9), 812. https://doi.org/10.3390/pathogens13090812

Vancouver

Ayala A, Llanes A, Lleonart R, Restrepo CM. Advances in Leishmania Vaccines: Current Development and Future Prospects. Pathogens. 2024;13(9):812. doi:10.3390/pathogens13090812

BibTeX
@article{Ayala2024,
  author = {Ayala, Andreina and Llanes, Alejandro and Lleonart, Ricardo and Restrepo, Carlos M},
  title = {Advances in Leishmania Vaccines: Current Development and Future Prospects},
  journal = {Pathogens},
  year = {2024},
  volume = {13},
  number = {9},
  pages = {812},
  doi = {10.3390/pathogens13090812}
}
Kostenlos starten →